中药癌热宁栓剂治疗癌性发热30例临床观察

目的 观察中药癌热宁栓剂治疗癌性发热的临床疗效。方法采用随机对照方法将54例癌性发热患者分成观察组（30例）和对照组（24例），观察组予中药癌热宁栓剂纳肛，对照组以消炎痛栓剂纳肛，7天为1个疗程。停药7天后，用放射免疫法检测血清肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）水平；检查血、尿、便常规及肝、肾功能；观察患者治疗前后体温、临床主症的变化及不良反应。 结果 两组降热有效率分别为86.7%和66.7%，差异有统计学意义(χ²=8.06，P< 0.05)，观察组治疗后患者血清TNF-α、IL-1β水平明显低于对照组(t=7.477、t=3.492，P<0.01)，并且能够明显改善患者临床主要症状(t=4.71，P<0.05)，提高患者生活质量(χ²=7.38，P<0.05)，与对照组比较差异均有统计学意义。对外周血象无明显影响，并未见明显心、肝、肾功能损害。结论 中药癌热宁治疗癌性发热，退热作用持久而稳定，无明显不良反应，值得临床使用和推广。

Clinical Observation of Airening Suppository in Treatment of 30 Patients with Carcinoma Fever

OBJECTIVE: To observe the clinical therapeutic effect of Airening Suppository (ARN) on carcinoma fever. METHODS: Adopting randomized and double-blinded method, 54 patients with carcinoma fever were randomly assigned to the observation group and the control group, who were treated respectively with ARN and indomethacin suppository by anal administering, 7 days as one treatment course. The effect on body temperature on patients and side effect occurred were observed 7 days after discontinuation of the medication, and patients' serum tumor necrosis factor alpha (TNF-alpha), interleukin-1beta were determined by RIA, routine test of blood, urine and stool, liver and renal function were tested as well. Body temperature, changes of clinical symptoms, and adverse reaction were observed. RESULTS: The effective rate of fever abating was 86.7% in the observation group and 66.7% in the control group, showing significant difference between them (chi2 = 8.06, P <0.05). After treatment, serum levels of TNF-alpha and IL-1beta in the observation group were much lower than those in the control group (t = 7.477, t = 3.492, P <0.01). Besides, patients' chief clinical symptoms and quality of life were markedly improved in the observation group (t =4.71, P <0.05, chi2 =7.38, P <0.05), all better than those in the control group (P < 0.05). No evident effect on peripheral blood figure, or harmful impact on heart, liver and kidney function was found. CONCLUSION: Airening Suppository has a standing and stable fever abating effect in treating cancerous fever with no obvious adverse reaction, so it is worthy of clinical use and spreading.